|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| (11) | Number of the document | 3119431 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15765287.6 |
| Date of filing the European patent application | 2015-03-20 | |
| (97) | Date of publication of the European application | 2017-01-25 |
| (45) | Date of publication and mention of the grant of the patent | 2024-01-24 |
| (46) | Date of publication of the claims translation | 2024-03-12 |
| (86) | Number | PCT/US2015/021887 |
| Date | 2015-03-20 |
| (87) | Number | WO 2015/143409 |
| Date | 2015-09-24 |
| (30) | Number | Date | Country code |
| 201461968897 P | 2014-03-21 | US | |
| 201462083809 P | 2014-11-24 | US | |
| 201562119778 P | 2015-02-23 | US |
| (72) |
BIGAL, Marcelo , US
WALTER, Sarah , US
STERN, Henry , US
CHANG, Michael , US
|
| (73) |
Teva Pharmaceuticals International GmbH ,
Schlüsselstrasse 12, 8645 Rapperswil-Jona,
CH
|
| (74) |
Otilija KLIMAITIENĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai |
| ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME |
| Payment date | Validity (years) | Amount | |
| 2025-02-18 | 11 | 289.00 EUR |
| 2026-03-20 |